Abiopharma

ELANCO ANIMAL HEALTH INC (ELAN) Reports the reporting period Financial Results ELANCO ANIMAL HEALTH INC (ELAN) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: (9)
• Net Income: 57
• EPS: 204
• Cash and equivalents: 428
  • Credelio Quattro™ accelerated dollar share gains of broad
  • spectrum sales out of U.S. vet clinics in Q1, up 3 points versus Q4
  • *; penetrated over 40% of the U.S. clinic base; 53% share in U.S. clinics that carry Quattro, up 13 points in Q1 versus Q4 Management Commentary: '"Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons'
    • expected in Q2•Added Costco and Dollar General as new retail customers for parasiticides in the U.S.•Advantage® Collar for Dogs launched in April, providing four-month protection against fleas and ticks, available at pet specialty, dollar, grocery, and mass retailers1•Closed the previously announced acquisition of AHV International on April 30th**Per Kynetec data***Internal estimates based on multiple data sourcesFinancial ResultsFirst Quarter Results(dollars in millions, except per share amounts)2026